Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.45 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27741454 | 0.94 | DEGS1 (0.50) | RAB9APOLBHPGDLMNACA1 | |
| SCHEMBL27761922 | 0.86 | SOAT1 (0.56) | HPGDMAPK1 | |
| SCHEMBL5029721 | 0.85 | DEGS1 (0.49) | RAB9APOLBHPGDLMNACA1 | |
| SCHEMBL18773443 | 0.82 | MAP4K4 (0.47) | POLBHPGDLMNAMAPKAPK2CA12 | |
| SCHEMBL9667337 | 0.79 | XDH (0.50) | SMN1; SMN2RAB9AMAPK10POLBHPGD | |
| SCHEMBL15500735 | 0.79 | L3MBTL1 (0.37) | MAPKAPK2L3MBTL1 | |
| SCHEMBL27761916 | 0.79 | PSMB11 (0.54) | HPGDGLAMAPK1 | |
| SCHEMBL9318764 | 0.75 | SMN1; SMN2 (0.47) | SMN1; SMN2RAB9AMAPK10POLBLMNA | |
| SCHEMBL12968430 | 0.74 | CA1 (0.51) | POLBCA12CA1CA2CA9 | |
| SCHEMBL5651536 | 0.73 | SMN1; SMN2 (0.51) | SMN1; SMN2RAB9AMAPK10LMNAMAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569566-B2 | Compositions containing, methods and uses of antibody-TLR agonist conjugates | AMBRX, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| CN-119455004-A | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119455003-A | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-113660957-B | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| CN-116457023-A | antibody-TLR agonist conjugates, methods and uses thereof | AMBRX公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-4199968-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | Ambrx, Inc. (US) | 2023-06-28 | — | — | EP | disclosed |
| US-20220226488-A1 | COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES | AMBRX, INC. | 2022-07-21 | — | — | US | disclosed |
| WO-2022040596-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | SMN1; SMN2 2161/4885RAB9A 2030/4885MAPK10 1267/4885 |
| US-20220226488-A1 | COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES | TLR1, TLR3, TLR2 | SMN1; SMN2 3078/4885RAB9A 2614/4885MAPK10 440/4885 |
| US-12569566-B2 | Compositions containing, methods and uses of antibody-TLR agonist conjugates | TLR3, TLR2, TLR1 | SMN1; SMN2 4495/4885RAB9A 4220/4885MAPK10 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.